A miss is a miss
21/03/24 -"BioNTech reported weaker than expected FY23 sales figures (-17.7%), explained by the structure of the partnering deal with Pfizer. However, investors were not amused and the shares dropped by -5%. We ..."
Pages
52
Language
English
Published on
21/03/24
You may also be interested by these reports :
26/04/24
The Q1 profits surpassed the street’s expectations, as all the three key molecules witnessed decent growth. Segment-wise, Spain and International ...
26/04/24
Hikma’s qualitative Q1 commentary entailed a positive tone for all the segments. Moreover, the management reaffirmed the full-year guidance. Since ...
25/04/24
The Q1 results topped expectations, led by robust performances across all the key segments. While the management maintained its 2024 guidance, an ...
25/04/24
Q1 results surpassed expectations, on the back of a strong showing from immunology drug Dupixent, RSV vaccine Beyfortus and the new launches of ...